Type 2 diabetes has been identified as a risk factor for Alzheimer's disease (AD). Insulin signalling is often impaired in AD, contributing to the neurodegeneration observed in AD patients. One potential strategy to overcome this impairment is to normalise insulin signalling in the brain. In the present study, we have examined the effects of an enzymeresistant analogue of glucose-dependent insulinotropic polypeptide (GIP), N-AcGIP, on synaptic plasticity. N-AcGIP is stable, long-acting peptide hormone that regulates glucose homeostasis and insulin release. We tested the effects of native GIP and the agonist N- 
Introduction
Type 2 diabetes has been identified recently as a risk factor for developing Alzheimer's Disease (AD) (Biessels and Kappelle 2005; Li and Hölscher 2007) . For example, an analysis of the Mayo clinic patient data base showed a clear correlation between AD and Type 2 diabetes. About eightyfive percent of AD patients also had diabetes or impaired fasting glucose levels (Janson et al. 2004) .
A different study found that the occurrence of AD is doubled in diabetic subjects (Ott et al. 1999) .
Type 2 diabetes is often associated with the desensitisation of insulin receptors, thereby compromising insulin signalling and cell metabolism. Desensitisation of insulin receptors has been observed in the brains of AD patients (Biessels et al. 2006; Carro and Torres-Aleman 2004) , and neuronal glucose and energy metabolism is impaired in early stages of AD (Steen et al. 2005 ). In addition, it was found that late-onset sporadic AD disease changes in the brain are similar to those caused by Type 2 diabetes (Hoyer 2004) . Recently, it has been shown that beta-amyloid fragments bind to insulin receptors in the brain, and cause a strong reduction of receptor numbers on dendrites (Zhao et al. 2007 ). This could be part of the underlying basis for the link between AD and type 2 diabetes.
The role of insulin receptors in the brain have been under investigation for many decades. It has been found that diabetes is associated with cognitive deficits, and that insulin given to diabetic or non-diabetic people improves attention and short term memory (Hoyer 2004; Stockhorst et al. 2004; Strachan 2005) . People with diabetes have reduced global memory, attention, abstract reasoning, and visual motor task performance (Trudeau et al. 2004) . In animal models of diabetes, memory impairments have been observed in learning spatial tasks and furthermore, treatment with insulin was shown to reverse these impairments. Long-term potentiation of synaptic transmission (LTP) in the hippocampus of diabetic animals was found to be impaired and in one study, 12 weeks after streptozotocin treatment to induce diabetes, NMDA-dependent LTP in area CA3 and CA1 was impaired (Gispen and Biessels 2000; Trudeau et al. 2004) . Studies in our laboratory have demonstrated that beta-amyloid, the peptide that aggregates to form plaques in the brain of AD patients, also affects the induction of LTP in the hippocampus. Low amounts of different fragments of amyloid injected icv. can impair or block LTP in the hippocampus in vivo in a fast and immediate time course (Freir et al. 2001; Gengler et al. 2006 ). This impairment also affects the ability to learn spatial tasks and is reversible (Hölscher et al. 2007 ).
It is therefore of interest to investigate in further detail the role of insulin signalling on synaptic plasticity, and whether insulin-signalling can alter the impairment of LTP induced by beta-p 4 amyloid fragments. Since insulin affects blood glucose concentrations, which on its own can have powerful effects on neuronal activity, we did not attempt to activate the insulin receptor directly.
Instead, we chose to employ a novel strategy examining the effects of the insulinotropic hormone, glucose-dependent insulinotropic polypeptide (GIP), and an enzyme-resistant analogue on synaptic plasticity. GIP is a 42-amino acid peptide hormone whose major physiological role is targeting pancreatic islets to enhance insulin secretion and help reduce postprandial hyperglycaemia (Gault et al. 2003) . In addition to its actions in modulating insulin release, GIP has been shown to promote pancreatic beta-cell growth, differentiation, proliferation and survival (Gault et al. 2003) .
Furthermore, GIP elicits several physiologically important glucose-lowering actions through a variety of extrapancreatic mechanisms (Irwin et al. 2008) . Taken together, these beneficial actions highlight GIP as an attractive therapeutic approach for Type 2 diabetes. However, GIP is rapidly degraded in the circulation by the enzyme, dipeptidylpeptidase-IV (DPP-IV), and as such, stable, enzyme-resistant forms have recently been developed (Irwin et al. 2008 ).
Interestingly, GIP receptors are expressed in the brain, including the hippocampus, and are found on neurons and on neuronal progenitor cells in the hippocampus (Nyberg et al. 2005; Nyberg et al. 2007 ). We have previously have shown that GIP's sister incretin hormone, glucagon-like peptide-1 (GLP-1), has acute and prominent enhancing effects on LTP and can reverse the effects of beta-amyloid fragments on LTP in the hippocampus (Gault and Holscher, submitted). Since GIP has very similar properties to GLP-1, we decided to test the effects of GIP and a stable analogue on LTP induction in the hippocampus. The effects of a novel GIP antagonist Pro(3)GIP on LTP was also tested (Gault et al. 2005) . Furthermore, effects of N-AcGIP on impairment of LTP by the betaamyloid fragment (25-35) were examined.
Materials and Methods

Surgery and LTP induction protocols
Male Wistar rats (Harlan, UK) weighing 220-280g were anaesthetised with urethane (ethyl carbamate, 1.8 g/kg, i.p.) for the duration of all experiments. A cannula (22 gauge, 0.7 mm outer diameter, 11 mm in length, Bilaney, Kent, UK) was implanted (1.5 mm anterior to bregma, 0.5 mm lateral to the midline and 3.55 mm ventral) into the left hemisphere for icv injections. Electrodes HFS protocol for inducing LTP consisted of 10 trains of 10 stimuli, inter-stimulus interval 5 ms (200 Hz). The strong HFS was used to test the effects of peptides that impair LTP (beta-amyloid), and the weak HFS was used to test peptides that facilitate LTP. In this form of LTP, the control group is not potentiated at a maximal rate, and LTP can decay slowly over time.
Stimulation intensity was 70% of the max. EPSP. LTP was measured as % of baseline EPSP slope recorded over a 30 min period prior to drug injection and 60 min prior to application of HFS.
Baseline was recorded for 30 min and averaged. This value was taken as 100% of the EPSP slope and all recoded values were normalised to this baseline value. All experiments were licensed according to UK Home Office regulations, and the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985) were followed.
Peptides
Beta-amyoid (25-35) and other peptides used in this study were synthesised on an Applied BioSystems automated peptide synthesiser (Model 432A) using standard solid-phase Fmoc protocols. Peptides were judged pure by reversed phase HPLC on a waters Millenium 2010 chromatography system, and peptides were subsequently characterised using matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass spectrometry as described previously (Gengler et al. 2006; Hölscher et al. 2007 ). Peptides were stored in dry form and dissolved in double distilled water before the experiments. 5µl of peptides solution was injected icv.
Statistics
Each group consisted of 6 animals. Data had been analysed using a repeated measures two-way ANOVA, or a repeated measures three level two-way ANOVA with post-hoc tests to discriminate between groups (PRISM, GraphPad software Inc, USA). Data were analysed in the ANOVA ranged from post-HFS onwards until the end of recording, as not difference was expected pre-HFS. All data points post-HFS were included.
Results
Effects of GIP and N-AcGIP on LTP
The native hormone GIP was injected (15 nmol in 5µl icv.) to test the effects on LTP using a weak stimulation protocol (Control group 142%±8.3SEM of baseline values; GIP 179%±11.2SEM). A two-level two-way repeated measures ANOVA showed a difference between the GIP group and control (DF 1,10; F= 14.1; p<0.01) and over time DF 1,119 ; F= 1.7; p<0.01). Interaction between factors was not significant. All groups n=6. See fig. 1a .
The novel stable GIP agonist N-AcGIP was tested (15nmol in 5µl icv.) using a weak stimulation protocol. A two-level two-way repeated measures ANOVA showed a difference between the NAcGIP group LTP (133%±19.2SEM) and control (DF 1,10; F= 17.5; p<0.001; 180%±14.1SEM) and over time (DF 1, 119 ; F= 1.9; p<0.005). Interaction between factors was not significant (see fig. 1b ).
All groups n=6.
Effects of the antagonist (Pro 3 )GIP on LTP
As a control for this study, a GIP antagonist, (Pro 3 )GIP (Gault et al. 2002) , was tested (15 nmol in 5µl icv.) using a strong stimulation protocol.. A two-level two-way repeated measures ANOVA showed a difference between the (Pro 3 )GIP group and control (DF 1,10; F= 21; p<0.001) and over time (DF 1, 119 ; F= 1.96; p<0.005). Interaction between factors was not significant (see fig. 2 ). All groups n=6.
Effects of N-AcGIP on the impairment of LTP by beta-amyloid(25-35)
When injecting either 100 nmol or 10 nmol beta-amyloid(25-35) icv, a significant difference on LTP induced by a strong stimulation protocol was found compared to a control group that was injected with an inactive scrambled peptide sequence version of beta-amyloid( Fig. 3 ).
Drug effects on LTP induction
In order to investigate whether the drugs increase LTP of fEPSPs in absolute terms or increase the likelihood of inducing LTP (but not increasing LTP in absolute terms), the average LTP results for each animal has been drawn up in a scatter plot. The plot shows that the effect of the GIP ligands has a general effect on each group, increasing or decreasing the amount of overall LTP for all animals, rather than increasing the probability of inducing LTP in a rat ( fig. 4 ).
Discussion
The results show for the first time that GIP and the stable analogue N-AcGIP have direct and acute modulating effects on synaptic transmission and can enhance the induction of LTP. The novel stable antagonist Pro(3)GIP has detrimental effects on LTP. The fact that the GIP receptor agonists enhance LTP and the GIP antagonist reduces LTP suggests that the effects of these peptides are due to the activation or the block of neuronal GIP receptors. The enhancing effect of LTP triggered by the activation of GIP receptors could be the result of modulation of vesicle release at the presynaptic site. Similar to modulating the release of insulin under hyperglycaemic conditions, GIP receptor activation would only modulate transmitter release, which explains the lack of effects on basic transmission while enhancing LTP after HFS. We know that GIP receptors on beta-cells in the pancreas modulate insulin release via a mechanism that involves closure of K + channels, depolarisation of the cell membrane which activates voltage-dependent calcium channels (VDCC), and the increase of cAMP levels. The subsequent influx of Ca 2+ then activates Ca 2+ sensitive enzymes such as PLA 2 , PLC, adenylate cyclase that form cAMP, and PKA, and activates the mechanisms of vesicle exocytosis to release insulin into the extra-cellular space (Green et al. 2004; Leech and Habener 1997; Suzuki et al. 1997; Irwin et al. 2005a; Irwin et al. 2005b) ). The same biochemical mechanisms that control the release of neurotransmitters into the synaptic cleft via vesicles are found in neurons (Okamoto et al. 1994; Wheeler et al. 1994; Winder and Conn 1993) .
Indeed, it has been shown that in neuronal cell cultures, the incretin GLP-1 that part of the hormone family to which GIP belongs, also modulates glutamate-induced Ca 2+ influx. This effect is due to altered VDCC activity. Ca 2+ influx induced by K + conductance is also altered. GLP-1 furthermore induces cAMP formation, activates PKA, MAPkinases and more (Gilman et al. 2003) . In addition, insulin receptors have been identified at the presynaptic site (Zhao et al. 2007 ), and they also modulate the release of neurotransmitter in neurons and affect the induction of LTP in the hippocampus (Gispen and Biessels 2000; Li and Hölscher 2007) . We therefore postulate that the mechanism by which GIP increases insulin release in the pancreas is similar to the effects on LTP and synaptic transmission observed in the present study in the brain. However, other mechanisms of action are feasible, and our theory will have to be tested by further experiments.
Beta-amyloid fragments also have been shown to affect synaptic transmission. Beta-amyloid has detrimental effects on LTP (Freir et al. 2001) . The underlying mechanism of this impairment include the change of K + channel activity (Jalonen et al. 1997; Pannaccione et al. 2004) 1995; Harris et al. 1996) . Interestingly, the release of beta-amyloid is affected and reduced by GLP-1 (Perry et al. 2003) .
The results of the present study also show that the facilitating effects of GIP on synaptic plasticity can prevent the detrimental effects that beta-amyloid(25-35) fragments have on LTP. The fact that GIP has to be applied at least 30 min before beta-amyloid makes it unlikely that both compounds act at the same binding sites on neurons. Instead, it appears that the activation of GIP receptors triggers mechanisms that prime synapses for increased LTP and prevent or counteract the effects that beta-amyloid has on synaptic plasticity by altering VDCC and other ion channel activity. A possible mechanism would be that GIP activates cAMP levels in neurons in a similar way that it activates in beta cells (Green et al. 2004) . The cAMP increase then can enhance vesicle release and makes synaptic activity less dependent on VDCC activity, which is affected by betaamyloid (Freir and Herron 2003) . Since the chronically increased activation of Ca 2+ channels leads to neurotoxic processes such as the increased production of free radicals (Hölscher 2005 (Hölscher , 1998 , the observation that GIP receptor activation prevents the effects of beta-amyloid holds the great promise that the early degenerative effects of beta-amyloid can be reduced, and the downstream processes that lead to neurodegeneration can be prevented. In addition, the growth factor-like effects that GIP has on neurons by increasing stem cell proliferation and neuronal regeneration could help prevent or reduce long-term damage induced by beta-amyloid activity and plaqueinduced gliosis (Perry and Greig 2005; Perry et al. 2003) . These properties of GIP suggest that the treatment of AD patients with stable GIP agonists could be an effective prophylactic treatment of Alzheimer's disease. However, further research is required to identify the underlying biochemical processes of the acute and chronic GIP effects in the CNS. 
Fig 2:
The GIP antagonist (Pro 3 )GIP had been tested (15nmol in 5µl icv.) using a strong stimulation protocol.. An ANOVA showed a difference between the (Pro 3 )GIP group and control (p<0.001). Averaged EPSPs are shown recorded 5 min pre-HFS and 1 h post-HFS. Calibration bars are 10ms horizontal, 1mV vertical. All groups n=6. 
Fig. 4:
In order to analyse the increase of probability of the induction of LTP, the fEPSP averages pre and post HFS of each rat are plotted. Average fEPSP increases after HFS are shown for each animal of each group. The drugs appear to increase (or decrease) overall LTP across each group, rather than change the probability of inducing LTP. Shown are results from the control group using a weak HFS protocol (control weak) and the GIP group (see fig. 1a ), the N-acGIP group ( fig. 1b) , the (Pro 3 )-GIP group ( fig. 2) , the beta-amyloid group (100nmol dose), and the drug combination of (Pro 3 )-GIP and beta-amyloid (100nmol), (see fig. 3 ).
